Vertex Pharmaceuticals Interest Income Over Time

VRTX Stock  USD 464.56  2.51  0.54%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vertex Pharmaceuticals Performance and Vertex Pharmaceuticals Correlation.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.
  
Interest Income is likely to rise to about 645.4 M in 2024. Net Interest Income is likely to rise to about 599.1 M in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.01
Earnings Share
(1.90)
Revenue Per Share
41.185
Quarterly Revenue Growth
0.116
Return On Assets
0.1205
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Interest Income Analysis

Compare Vertex Pharmaceuticals and related stocks such as Biomarin Pharmaceutical, Sarepta Therapeutics, and Seagen Inc Interest Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
BMRN34.6 M34.6 M34.6 M34.6 M34.6 M34.6 M7.5 M14.9 M22.8 M22.7 M16.6 M10.5 M18 M49 M51.5 M
SRPT154 K154 K154 K154 K154 K154 K535 K1.8 M6.8 M7.2 MM354 K16.5 M67.7 M71 M
ALNY5.9 M5.9 M5.9 M5.9 M5.9 M5.9 M8.3 M12.2 M29.3 M33.4 M11.8 M1.6 M24.8 M95.6 M100.3 M
NTLA525 K525 K525 K525 K525 K525 K525 KM5.5 M6.8 M2.4 M1.3 M8.5 M49.8 M52.3 M
EDIT143 K143 K143 K143 K143 K143 K62 K978 K3.4 M7.3 M2.6 M2.3 M4.2 M13.9 M14.6 M
BEAM292 K292 K292 K292 K292 K292 K292 K292 K292 K2.5 M2.5 M2.5 M2.5 M2.9 M1.5 M
DNA5.8 M5.8 M5.8 M5.8 M5.8 M5.8 M5.8 M5.8 M5.8 M5.8 M2.6 M837 K20.3 M57.2 M60.1 M
BNTX2.1 M2.1 M2.1 M2.1 M2.1 M2.1 M2.1 M2.1 MM1.8 M1.6 M1.5 M330.3 M357.6 M375.5 M
MRNA11.3 M11.3 M11.3 M11.3 M11.3 M11.3 M11.3 M15.2 M27 M38.5 M24.7 M18 M200 M405 M425.2 M
REGN14.2 M14.2 M14.2 M14.2 M14.2 M14.2 M7.2 M25.1 M13.7 M88.1 M45.8 M45.8 M160.1 M417.7 M438.6 M
VKTX982.2 K982.2 K982.2 K982.2 K982.2 K982.2 K1.9 M1.3 K3.2 MM3.2 M703 K1.6 M11 M11.6 M
PTCT2.4 M2.4 M2.4 M2.4 M2.4 M2.4 M8.3 M12.1 M12.6 M12.5 M12.5 M12.5 M12.5 M14.4 M10.5 M
KRYSKKKKKKK3.1 MMM832 K197 K5.2 M22.6 M23.8 M
MDGL3.6 M3.6 M3.6 M3.6 M3.6 M3.6 M48.3 K558 K7.7 M11 M4.3 M363 K2.2 M19.6 M20.6 M
CRSP108 K108 K108 K108 K108 K108 K44.6 M1.8 M4.3 M5.5 M5.5 M5.5 M5.5 M4.9 MM
CRBUMMMMMMMMMM236 K148 K148 K133.2 K126.5 K
VERV278 K278 K278 K278 K278 K278 K278 K278 K278 K278 K162 K76 K6.9 M7.9 M8.3 M

Vertex Pharmaceuticals and related stocks such as Biomarin Pharmaceutical, Sarepta Therapeutics, and Seagen Inc Interest Income description

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

My Equities

My Current Equities and Potential Positions

Vertex Pharmaceuticals
VRTX
ClassificationPharmaceutical Products
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 464.56

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.